A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
PURPOSE: BIM is essential for the response to tyrosine-kinase inhibitors (TKI) in chronic myeloid leukaemia (CML) patients. Recently, a deletion polymorphism in intron 2 of the BIM gene was demonstrated to confer an intrinsic TKI resistance in Asian patients. The present study aimed at identifying mutations in the BIM sequence that could lead to imatinib resistance independently of BCR-ABL mutations. EXPERIMENTAL DESIGN: BIM coding sequence analysis was performed in 72 imatinib-treated CML patients from a French population of our centre and in 29 healthy controls (reference population) as a case-control study. Real-time quantitative PCR (RT qPCR) was performed to assess Bim expression in our reference population. RESULTS: No mutation with amino-acid change was found in the BIM coding sequence. However, we observed a silent single nucleotide polymorphism (SNP) c465C>T (rs724710). A strong statistical link was found between the presence of the T allele and the high Sokal risk group (p = 0.0065). T allele frequency was higher in non responsive patients than in the reference population (p = 0.0049). Similarly, this T allele was associated with the mutation frequency on the tyrosine kinase domain of BCR-ABL (p<0.001) and the presence of the T allele significantly lengthened the time to achieve a major molecular response (MMR). Finally, the presence of the T allele was related to a decreased basal expression of the Bim mRNA in the circulating mononuclear cells of healthy controls. CONCLUSION: These results suggest that the analysis of the c465C>T SNP of BIM could be useful for predicting the outcome of imatinib-treated CML patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Responsiveness to anti-VEGF, corticosteroids, and tyrosine kinase inhibitors hinge on BIM function, with BIM polymorphisms negating effective treatment [27, 33, 39].”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The synonymous BIM polymorphism (rs724710) has a CC allele frequency that varies from 43–87% depending on the population background [28, 33, 40]”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“with higher basal BIM expression reported in individuals having this CC allele [27, 33].”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416
SNPStats: a web tool for the analysis of association studies
Solé, X., Guinó, E., Valls, J., Iniesta, R., & Moreno, V. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl268 · Cited by 2,006
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291 · cited 2×
“Optimal response, suboptimal response, and failure to imatinib first line therapy were defined according to the European Leukaemia net recommendations [1].”
BackgroundMethodXiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., Henderson, J. M., Kutok, J. L., & Rajewsky, K. (2008) · Nature Immunology · doi:10.1038/ni1575 · Cited by 1,228 · cited 1×
“T SNP could be located in the 39 untranslated terminal region (UTR) of the BIM gene and some of them could interfere with the miRNA binding [23,24].”
BackgroundHughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Bim: a novel member of the Bcl-2 family that promotes apoptosis
O'Connor, L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.384 · Cited by 1,166 · cited 2×
“Thus, the sequencing strategy (Figure S1b) focused on sequencing BIMEL, [11] the longest isoform generated by alternative splicing that contains coding information of the whole coding sequence.”
BackgroundMethodDuan, J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/12.3.205 · Cited by 930 · cited 1×
“folding and activity as previously suggested for the MDR1 and DRD2 genes [19–22].”
MethodMahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 584 · cited 2×
“The coding gene consists of 6 exons and 3 introns, and an alternative splicing of pre messenger RNA can generate several Bim isoforms [11,12].”
BackgroundSelf-citationNg, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557 · cited 3×
“This leads us to consider that some CML patients could have a genomic predisposition to poorly respond to treatment and thus could benefit from a personalized biological monitoring and treatment adaptation particularly associating BH3 mimetics to TKI as previously suggested [8,29] for compensating the Bim deficiency.”
BackgroundBim is a suppressor of Myc-induced mouse B cell leukemia
Egle, A., Harris, A. W., Bouillet, P., & Cory, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401471101 · Cited by 488
Research works printed but not linked: 2
- International HapMap project website. Available http://hapmap.ncbi.nlm.nih.gov/ Accessed 2008
- dbSNP website. Available http://www.ncbi.nlm.nih.gov/SNP/. Accessed 2008
Cited by
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
“This same polymorphism has also been associated with decreased duration of remission induced by imatinib in CML (131), and a separate polymorphism in the BIM BH3 domain has been identified that is associated with decreased BIM mRNA expression and prolonged time to major molecular response after initiation of imatinib…”
Tanimoto, A., Takeuchi, S., Arai, S., Fukuda, K., Yamada, T., Roca, X., Ong, S. T., & Yano, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2271 · Cited by 101
“Because the BIM deletion polymorphism induces apoptosis resistance, but not growth impairment, to EGFR-TKI exposure, tumors with the BIM deletion polymorphism may be permissive for the acquisition of additional resistance mechanisms, as recently demonstrated in chronic myeloid leukemia (CML; ref.”
BackgroundMutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia
Awad, S. A., Kankainen, M., & Mustjoki, S. M. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1894652 · Cited by 42
“be associated with TKI resistance [108], and they constitute an independent risk factor for inferior imatinib responses that can complement clinical risk scores in CP-CML patients [109,110].”
BackgroundZhang, A., Yu, J., Yan, S., Zhao, X., Chen, C., Zhou, Y. Y., Zhao, X., Hua, M., Wang, R., Zhang, C., et al. (2017) · Human Immunology · doi:10.1016/j.humimm.2017.10.013 · Cited by 39
“hematopoietic cells characterized by the BCR-ABL fusion gene, which results from a reciprocal t(9:22) chromosomal translocation [1-3].”
BackgroundDifferential Impacts of Alternative Splicing Networks on Apoptosis
Lin, J.-C., Tsao, M.-F., & Lin, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122097 · Cited by 41
“In addition, a cytosine-to-thymidine mutation (rs724710) within BIM exon 4 was noted to reduce the selection of exon 4 in lymphoblastic leukemia cells, which contributed to drug resistance [104].”
BackgroundMarum, J. E., Yeung, D. T. O., Purins, L., Reynolds, J., Parker, W. T., Stangl, D., Wang, P. P.-S., Price, D. J., Tuke, J., SCHREIBER, A. W., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006825 · Cited by 27
Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms
Czader, M., & Orazi, A. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpzqk40jozzzcc · Cited by 23
“Case 89 was a 73-year-old man with ET who developed leukemic transformation and a complex karyotype, including del(12) (p12p13) and i(17)(q10).”
BackgroundPlesa, M., Gagné, V., Glisovic, S., Younan, M., Sharif-Askari, B., Laverdière, C., Alos, N., Leclerc, J., Sallan, S. E., Neuberg, D. S., et al. (2017) · The Pharmacogenomics Journal · doi:10.1038/s41397-017-0002-4 · Cited by 23
Pharmacogenetics and the Treatment of Chronic Myeloid Leukemia: How Relevant Clinically? An Update
Ankathil, R., Azlan, H., Abdullah, A. D., & Baba, A. A. (2018) · Pharmacogenomics · doi:10.2217/pgs-2017-0193 · Cited by 18
Soh, S. X., Siddiqui, F. J., Allen, J. C., Kim, G. W., Lee, J. C., Yatabe, Y., Soda, M., Mano, H., Soo, R. A., Chin, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17102 · Cited by 19
“Of relevance to this discussion, functional polymorphisms in BIM besides the deletion polymorphism have been reported in other populations [43, 44].”
BackgroundEbi, H., Oze, I., Nakagawa, T., Ito, H. M., Hosono, S., Matsuda, F., Takahashi, M., Takeuchi, S., Sakao, Y., Hida, T., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000371 · Cited by 14
“In EGFR mutant lung cancer cell lines, genetic LOH and micro-RNA-mediated downregulation was shown to lead to low BIM expression.6,37 Additionally, other BIM polymorphisms may contribute to reduced BIM levels and efficacy of TKIs.38 Therefore, functional BIM is downregulated via different mechanisms in EGFR mutant lun…”
BackgroundInfluentialStiehler, S., Sembill, S., Schleicher, O. M., Marx, M., Rauh, M., Krumbholz, M., Karow, A., Suttorp, M., Woelfle, J., Maj, C., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284668 · Cited by 15
Soh, S. X., Lim, J. Y. S., Huang, J. W. J., Jiang, N., Yeoh, A. E. J., & Ong, S. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103435 · Cited by 11
“More recent work has also implicated other germline BIM variants in mediating drug resistance [48,49].”
BackgroundA new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line
Airiau, K., Turcq, B., Mahon, F., & Belloc, F. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.08.014 · Cited by 12
Self-citationMiyamura, K., Miyamoto, T., Tanimoto, M., Yamamoto, K., Kimura, S. H., Kawaguchi, T., Matsumura, I., Hata, T., Tsurumi, H., Saito, S., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.09.009 · Cited by 11
Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma
Wang, J. D., Katz, S. G., Morgan, E. A., Yang, D. T., Pan, X. J., & Xu, M. L. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.08.008 · Cited by 10
“For example, in chronic myeloid leukemia, Bim deletion polymorphisms lengthen the time for patients to achieve a major molecular response on tyrosine kinase inhibitors [19,20].”
BackgroundRegulatory network analysis of microRNAs and genes in imatinib-resistant chronic myeloid leukemia
Soltani, I., Gharbi, H., Hassine, I. B., Bouguerra, G., Douzi, K., Teber, M., Abbès, S., & Menif, S. (2016) · Functional & Integrative Genomics · doi:10.1007/s10142-016-0520-1 · Cited by 9
“T (rs724710), located in the BCL2L11 gene, was significantly associated with a longer delay to achieve a major molecular response, leading to more frequent mutations in the kinase domain of BCR-ABL and eventually to IM resistance (Augis et al. 2013).”
BackgroundLeo, E., Mancini, M., Castagnetti, F., Gugliotta, G., Santucci, M. A., & Martinelli, G. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25010 · Cited by 8
“BCL2-like11 dysfunction either due to an intronic deletion polymorphism or to a single nucleotide polymorphism (c465C> T) has been associated with CML resistance to IM [Ng et al., 2012; Augis et al., 2013; Katagiri et al., 2013].”
BackgroundThan, H., Lye, W. K., Sng, C., Allen, J. C., Ong, S. T., & Chuah, C. T. H. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1461863 · Cited by 9
“Unlike the single nucleotide polymorphic BIM variant reported in European CML populations [9], the BIM deletion polymorphism was uniquely observed in individuals of East-Asian origin with a carrier frequency of 12–20%.”
BackgroundWang, S., Zaitoun, I. S., Darjatmoko, S. R., Sheibani, N., & Sorenson, C. M. (2022) · Life · doi:10.3390/life12020208 · Cited by 7
“Individuals carrying a C→T substitution (c456C > T; T allele BIM BH3 single nucleotide polymorphism (SNP)) within the BIM BH3 domain (death-initiating domain) have lower basal Bim expression [38], while those with the C allele have higher basal Bim expression.”
BackgroundЛавров, А. В., Chelysheva, E., Adilgereeva, E. P., Shukhov, O. A., Smirnikhina, S., Kochergin-Nikitsky, K. S., Yakushina, V. D., Tsaur, G., Mordanov, S. V., Turkina, A., et al. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0481-z · Cited by 6
Sorenson, C. M., Gurel, Z., Song, Y.-S., Peterson, K. D., Blodi, B. A., & Sheibani, N. (2024) · PLOS ONE · doi:10.1371/journal.pone.0297135 · Cited by 5
Krishnan, V., Shyamsunder, P., & Ong, T. S. (2026) · Haematologica · doi:10.3324/haematol.2025.287767 · Cited by 4
Baccarani, M., Gugliotta, G., Castagnetti, F., Soverini, S., & Rosti, G. (2016) · Hematologic malignancies · doi:10.1007/978-3-319-33198-0_4 · Cited by 6
Gugliotta, G., Castagnetti, F., Soverini, S., Rosti, G., & Baccarani, M. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-71913-5_10 · Cited by 5
Ariyasu, R., Yanagitani, N., Tadokoro, K., Yamaguchi, T., Uchibori, K., Kitazono, S., Fujita, N., Katayama, R., & Nishio, M. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04136-7 · Cited by 3
Sheibani, N., Song, Y., Farnoodian, M., Inampudi, S., Hanna, B. A., Wang, S., Darjatmoko, S. R., & Sorenson, C. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910254 · Cited by 2
“BIM polymorphisms that lack a functional BH3 domain decrease BIM expression, causing dexamethasone and many other cancer treatments to be ineffective [10].”
BackgroundGenetic Determinants of Treatment‐Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia
Abaji, R., Gagné, V., Espagne, E., Alos, N., Vecchio, V. D., Said, L. A., Shalmiev, A., Fuchs, C., Laverdière, C., Leclerc, J., et al. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70371 · Cited by 2
“43 Functional defects in Bim protein isoforms may have different consequences, including increased apoptosis of bone cells.”
Pantoja, K. B. C. C., Azevedo, T. C. D. B., Vinagre, L. W. M. S., de Moraes, F. C. A., Nunes, G. G. D. C., Monte, N., de Alcântara, A. L., Cohen-Paes, A. D. N., Fernandes, M. R., dos Santos, S. E. B., et al. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04689-x · Cited by 2
“…BCR-ABL gene every three months, where the num - ber of copies of the mutated gene is evaluated and according to the guidelines it is possible to determine the response or resistance to treatment [ 43]. known that leukemic cells with decreased BIM expression are not good responders to TKIs [ 33].”
Katagiri, S., Umezu, T., Tauchi, T., & Yamamoto, T. (2014) · Cited by 2
Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance
Than, H., Chuah, C. T. H., & Ong, S. T. (2015) · Springer eBooks · doi:10.1007/978-4-431-55714-2_11 · Cited by 1
Katagiri, S., Tadokoro, K., Ohyashiki, J. H., & Ohyashiki, K. (2015) · Cited by 2
Biomarkers for Determining the Prognosis of CML
Takahashi, N. (2015) · Springer eBooks · doi:10.1007/978-4-431-55714-2_5
Sheibani, N., Wang, S., Darjatmoko, S. R., & Sorenson, C. M. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.111152
Bhattarai, A., Kountouris, D., Sah, S., Mehta, R., & Sah, R. (2026) · eJHaem · doi:10.1002/jha2.70372
“By shifting the splicing machinery back toward the production of the BIM-alpha isoform, these drugs can re-sensitize leukemic cells to TKIs, highlighting a clear molecular rationale for combination therapy in deletion cohorts [ 15, 19, 22, 26 ].”
Metadata
- Authors
- Augis, V., Airiau, K., Josselin, M., Turcq, B., Mahon, F.-X., & Belloc, F.
- Affiliations
- Inserm (FR)
- Corresponding author
- Augis, Vanessa
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-11-05
- Volume
- 8
- Issue
- 11
- Pages
- e78582
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3818406
- OpenAlex
- W2079281117
- Cited by
- 35
- References
- 25
- Citations by year
- 2026: 3 · 2024: 4 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 5 · 2016: 5 · 2015: 5 · 2014: 4
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ligue Contre le Cancer
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- chronic myeloid leukemia, imatinib, single nucleotide polymorphisms, major molecular response, imatinib resistance, BCR-ABL mutations, tyrosine kinase inhibitors, prognostic factors
- MeSH terms
- Imatinib Mesylate, Bcl-2-Like Protein 11, Adolescent, Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Benzamides, Child, Child, Preschool, Female, Gene Frequency, Humans, Leukocytes, Mononuclear, Male, Membrane Proteins, Middle Aged, Piperazines, Proto-Oncogene Proteins, Pyrimidines, RNA, Messenger, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Gene Expression, Case-Control Studies, Fusion Proteins, bcr-abl, Polymorphism, Single Nucleotide, Apoptosis Regulatory Proteins, Biomarkers, Pharmacological, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.